There are currently 2694 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
NCT04998396
Recruiting
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Gender:
ALL
Ages:
30 months and below
Trial Updated:
10/21/2024
Locations: Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND), Boston, Massachusetts
Conditions: Canavan Disease
Register for Updates
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
NCT05265429
Recruiting
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Gender:
ALL
Ages:
Between 15 years and 45 years
Trial Updated:
10/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
Register for Updates
Understanding Chronic Lymphocytic Leukemia
NCT04028531
Recruiting
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Intervention to Improve HIV Self-care Among People Who Inject Drugs
NCT05819411
Recruiting
This study will implement a pilot randomized controlled trial (RCT, N=70) to refine and assess the feasibility and acceptability of an emotion regulation and communication skills intervention designed to improve engagement in HIV-care among substance using HIV+ PWID sub-optimally engaged in HIV care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Fenway Community Health, Boston, Massachusetts
Conditions: Hiv, Substance Use Disorders
Register for Updates
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
Recruiting
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
10/17/2024
Locations: New England College of Optometry, Boston, Massachusetts
Conditions: Myopia
Register for Updates
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
NCT01356290
Recruiting
Patients with relapsed medulloblastoma, ependymoma and ATRT have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly... Read More
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/17/2024
Locations: Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts
Conditions: Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
NCT03936335
Recruiting
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
10/16/2024
Locations: Regeneron Research Site, Boston, Massachusetts
Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Register for Updates
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700
Recruiting
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumors
Register for Updates
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
NCT05866302
Recruiting
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the ons... Read More
Gender:
ALL
Ages:
36 months and above
Trial Updated:
10/15/2024
Locations: Dana Farber, Boston, Massachusetts
Conditions: Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Register for Updates
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04946370
Recruiting
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor pathway inhibitor (ARPI) is more effective against prostate cancer than pembrolizumab + ARPI alone.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
10/15/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
NCT05428839
Recruiting
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with obstructive sleep apnea who are being evaluated for airway surgery. Subjects will undergo standard evaluation for airway surgery as part of standard of care. In addition to the standard airway assessment, a simple, non-invasive measurement of the width of the inside of each subjects mouth will be performed. This measurement takes 2-3 minutes to perform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Conditions: Sleep Apnea, Obstructive
Register for Updates
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates